Tiragolumab

Generic Name: Tiragolumab

Drug Type: Biotech

CAS Number: 1918185-84-8

Unique Ingredient Identifier: 6XG22YQM2Z

Background: Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).

Clinical Trials

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Phase 2

Active, not recruiting

Conditions: PD-L1-selected Solid Tumors

Interventions: Drug: Tiragolumab and Atezolizumab IV FDC

First Posted Date: 2022-12-22

Last Posted Date: 2025-04-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 60

Registration Number: NCT05661578

Locations: 🇺🇸
Medical Oncology Associates, Spokane, Washington, United States
🇨🇳
Chongqing Sanxia Central Hospital, Chongqing City, China
🇨🇳
Tianjin Cancer Hospital, Tianjin, China

and more 35 locations

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Phase 2

Active, not recruiting

Conditions: Urothelial Cancer

Interventions: Drug: Atezolizumab
Drug: Tobemstomig
Drug: Tiragolumab

First Posted Date: 2022-12-09

Last Posted Date: 2025-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 204

Registration Number: NCT05645692

Locations: 🇩🇰
Aarhus Universitetshospital, Aarhus N, Denmark
🇬🇧
Royal Marsden Hospital, London, United Kingdom
🇬🇧
Royal Preston Hosptial, Preston, United Kingdom

and more 58 locations

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors

Phase 2

Recruiting

Conditions: MSI-H Cancer
Melanoma
Head and Neck Neoplasms

Interventions: Drug: Tiragolumab and atezolizumab

First Posted Date: 2022-08-02

Last Posted Date: 2025-03-30

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 97

Registration Number: NCT05483400

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2022-07-14

Last Posted Date: 2024-08-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT05459129

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺
Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷
Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France

and more 14 locations

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Metastatic Malignancy

Interventions: Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2022-05-27

Last Posted Date: 2025-04-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT05394337

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Non-Hodgkin Lymphoma, Follicular Lymphoma

Interventions: Drug: Mosunetuzumab SC
Drug: Tiragolumab
Other: Tocilizumab
Drug: Atezolizumab

First Posted Date: 2022-04-07

Last Posted Date: 2024-10-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 8

Registration Number: NCT05315713

Locations: 🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
CHU UCL Namur - Mont-Godinne, Yvoir, Belgium
🇩🇪
Universitaet Duisburg-Essen, Essen, Germany

and more 14 locations

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1

Recruiting

Conditions: Recurrent Rhabdoid Tumor
Refractory Epithelioid Sarcoma
Refractory Kidney Medullary Carcinoma
Refractory Malignant Solid Neoplasm
Epithelioid Sarcoma
Malignant Solid Neoplasm
Kidney Medullary Carcinoma
Recurrent Epithelioid Sarcoma
Recurrent Malignant Solid Neoplasm
Refractory Atypical Teratoid/Rhabdoid Tumor

Interventions: Biological: Atezolizumab
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Biological: Tiragolumab
Procedure: X-Ray Imaging

First Posted Date: 2022-03-18

Last Posted Date: 2025-05-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 86

Registration Number: NCT05286801

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States

and more 37 locations

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Phase 1

Recruiting

Conditions: Metastatic Bladder Cancer
Metastatic Non Small Cell Lung Cancer
Metastatic Renal Cell Carcinoma
Metastatic Head and Neck Cancer

Interventions: Drug: Atezolizumab 60 MG/1 ML Intravenous Solution [TECENTRIQ]
Drug: Tiragolumab
Radiation: Stereotactic body radiation therapy (SBRT)

First Posted Date: 2022-02-28

Last Posted Date: 2023-10-17

Lead Sponsor: Centre Georges Francois Leclerc

Target Recruit Count: 92

Registration Number: NCT05259319

Locations: 🇫🇷
Centre Georges François Leclerc (CGFL), Dijon, Bourgogne, France

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Phase 1

Active, not recruiting

Conditions: Gastric and Gastroesophageal Junction Carcinoma

Interventions: Drug: Atezolizumab
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Tiragolumab

First Posted Date: 2022-02-23

Last Posted Date: 2025-04-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT05251948

Locations: 🇨🇳
The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China
🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou City, China
🇨🇳
the First Hospital of Jilin University, Changchun, China

and more 9 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Phase 1

Completed

Conditions: Melanoma

Interventions: Drug: RO7247669 600 mg
Drug: RO7247669 2100 mg
Drug: Atezolizumab
Drug: Nivolumab
Drug: Ipilimumab
Drug: Tiragolumab

First Posted Date: 2021-11-10

Last Posted Date: 2024-10-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 110

Registration Number: NCT05116202

Locations: 🇦🇺
Melanoma Institute Australia, North Sydney, New South Wales, Australia
🇺🇸
The Angeles Clinic and Research Institute - W LA Office, Los Angeles, California, United States
🇮🇹
Ospedale S.Maria della Misericordia, Perugia, Umbria, Italy

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy